We are proud to announce that Optellum has been named winner of the Clinical Excellence & Evidence Award at the MedTech World Asia Awards 2026, held as part of MedTech World Asia 2026 in Hong Kong, from 26 to 28 August.
This recognition reflects the hard work, innovation, and dedication of our entire team, and we are honored to be celebrated alongside so many outstanding startups, scale-ups, digital health platforms, diagnostics pioneers, investors, and the leaders driving healthcare innovation across Asia and beyond.
"Clinical evidence is the foundation of everything we build," said Johnathan Watkins, CEO of Optellum. "Clinicians make decisions about a patient's lung nodule that change the odds of surviving lung cancer. An award for clinical excellence and evidence is recognition of the physicians, hospitals and researchers who have held our AI to that standard alongside us."
The MedTech World Awards are known for their credibility and rigor. This year, more than 5,500 public votes were cast across the various award categories, reflecting genuine engagement from the global MedTech community. From there, finalists were carefully shortlisted, and a Steering Committee selected the ultimate winners through an expert, criteria-based evaluation process.
Being chosen from a shortlist that included so many respected industry leaders and having our work assessed by a panel of experts makes this achievement even more meaningful to us. It is truly an honor to be recognized on a global platform like MedTech World, alongside companies that are pushing the boundaries of what's possible in health innovation.
Beyond the recognition itself, the MedTech World Awards gala was an experience in its own right. From the energy in the room to the calibre of attendance, the evening brought together founders, investors, clinicians, and innovators from across the MedTech ecosystem.
A particular highlight was the event's signature charity auction, which added a meaningful and heartfelt dimension to the evening, reminding everyone in the room why this industry does what it does. Between the ceremony, the networking, and the opportunity to book 1:1 meetings with other attendees, the gala offered far more than an awards presentation. It was a genuine opportunity to connect, exchange ideas, and build relationships that we expect will shape our work for years to come.
We are already looking forward to the next MedTech World event and to continuing to be part of a community so clearly committed to advancing MedTech innovation on a global scale.
Thank you to the MedTech World team, the Steering Committee, and everyone who voted to make this recognition possible.
Optellum is a commercial-stage AI healthcare company dedicated to revolutionizing early diagnosis and treatment of lung disease, starting with one of the deadliest, lung cancer.
Optellum's flagship product, Virtual Nodule Clinic (VNC) with Lung Cancer Prediction AI (LCP), is the world's first FDA-cleared and reimbursed software-as-a-medical-device (SaMD) solution for AI-powered lung cancer prioritization and diagnostic support. Clinicians trust the Optellum solution to aid them in making the most appropriate life-saving treatment decisions for their patients. Backed by real-world clinical evidence, Optellum's solution accelerates the diagnostic care pathway by enabling early patient identification, enhancing prioritization, and improving clinicians' efficiency, reducing time to guideline-recommended treatment. Optellum VNC is FDA cleared, CE-MDR marked, UKCA marked, and TGA-approved.
Optellum is headquartered in Oxford, UK, and has an office at the Texas Medical Center in Houston, Texas, US.
Media Contact:
Philippe Freund
Head of Marketing and Market Development
marketing@optellum.com